Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis by Jackson, Lauren R
Otterbein University 
Digital Commons @ Otterbein 
Nursing Student Class Projects (Formerly MSN) Student Research & Creative Work 
7-2016 
Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis 
Lauren R. Jackson 
Otterbein University, lauren.jackson@otterbein.edu 
Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn 
 Part of the Nursing Commons 
Recommended Citation 
Jackson, Lauren R., "Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis" (2016). Nursing 
Student Class Projects (Formerly MSN). 135. 
https://digitalcommons.otterbein.edu/stu_msn/135 
This Project is brought to you for free and open access by the Student Research & Creative Work at Digital 
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an 
authorized administrator of Digital Commons @ Otterbein. For more information, please contact 
digitalcommons07@otterbein.edu. 
Significance of Pathophysiology 
Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis
Lauren Jackson BSN, RN
Introduction
Progressive multifocal 
leukoencephalopathy (PML) is a rare and 
debilitating disease caused by the JC virus 
and results in demyelination of 
oligodendrocytes and glial cell lysis, leading 
to plaque development on the brain and 
neurological problems (Gorelik et al., 2011). 
PML develops in individuals who have an 
immune disorder and who have been 
treated with immunomodulatory 
medications. Such individuals include those 
affected with Multiple Sclerosis (MS) 
(Gorelik et al., 2011). MS is a disease that 
involves inflammation of the central 
nervous system and causes a progressive 
decline in neurological function and is 
believed to be a result of self-antigens and 
an autoimmune response (Keating & 
McCormack, 2014). There is no cure for MS 
and the majority of cases are classified as 
relapse-remitting (Major & Douek, 2013). 
The first-line medications used to treat 
MS show only a 30% reduction in relapses 
per year. Recently a new medication, 
Natalizumab, has shown a 68% reduction in 
relapses per year (Baldwin & Hogg, 2013). 
While Natalizumab shows promise in the 
treatment of MS, the drug has shown to 
increase the risk of development of PML, 
especially in long-term use (more than 18 
months) (Schwab et al., 2013). There is no 
cure for PML and 30-50% of patients who 
develop the disease die within the first few 
months of diagnosis. Those that survive, are 
typically left with severe neurological 
damage (National Institute of Neurological 
Disorders and Stroke [NINDS], 2015). 
As an Advanced Nurse Practitioner 
(ANP), the author will encounter patients 
diagnosed with MS, as MS is a fairly 
common neurological disorder with 1 in 
750 people in the United States at risk for 
developing the disease (National Multiple 
Sclerosis Society, n.d.).  These patients may 
be newly diagnosed or looking for new 
treatment options. Knowing the risk of PLM, 
signs and symptoms and its effects can 
assist the ANP and the patient in making an 
informed decision about their treatment 
options. 
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• Signs and symptoms of PML can vary greatly depending on the area of 
the brain that is affected (Berger et al., 2013). 
• Patients may initially present with distinct behavioral or cognitive 
changes that are reported by family members (Fitzgerald, 2015).
• Other neurological symptoms that can occur include hemiplegia, 
lethargy, aphasia, anxiety, fatigue, seizures, impaired memory and ataxia 
(Fine, Sorbello, Kortepeter, & Scarazzini, 2014).
• The disease continues to progress slowly over time with worsening 
symptoms, leading to death or neurological disabilities (NINDS, 2015). 
See Figure 1.
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The JC virus is a fairly common virus that many people are 
unaware they have been infected with and usually remains 
dormant for life. However, the virus can be reactivated in certain 
immunosuppressive conditions, as in MS and certain 
medications for its treatment, causing the development of PML 
(Gorelik et al., 2011). PML affects glial cells and creates 
lesions/plaques on the brain that can cause severe neurological 
disabilities and lead to death. There is no cure for the disease 
and treatment focuses on symptom management and attempting 
to slow the progression with plasma exchange (NINDS, 2015). A 
combination of MRI to look for PML associated lesions, 
cerebrospinal fluid analysis for antibodies and signs and 
symptoms lead to the diagnosis of PML (Fitzgerald, 2015). The 
APN should be aware that PML can develop in patients with MS 
and know what signs to look for and when further testing is 
needed. If PML is suspected, fast action and referral is needed by 
the APN.
Conclusion
• The APN should be aware that any patient presenting with a 
history of MS and taking natalizumab, can begin showing signs of 
PML at any time, particularly after long-term therapy. The APN 
should also be aware that when a patient with a history of MS 
presents with new symptoms, there is a chance that the 
symptoms may not be a result of MS, but of PML and quick action 
is needed (Fitzgerald, 2015). 
• Symptoms of MS relapse tends to develop quickly, over hours to 
days while PML symptoms occur more slowly (Fitzgerald, 2015). 
• MS responds to steroid therapy or levels off, whereas PML 
continues to progress despite treatment (Fitzgerald, 2015). 
• Most patients with MS are cared for by a specialist, however 
APNs may encounter these patients in family practice or even in 
the acute care setting and need to be aware of PML and its effects. 
Symptom management and attempting to improve quality of life 
may be a vital part of the APN’s role when dealing with a patient 
with PML. 
• APNs in family practice may encounter newly diagnosed 
patients with MS and needs to be able to discuss the treatment 
options and risks/benefits to assist their client during that 
difficult time. Therefore, an understanding of PML and its relation 
to MS is important. 
Implications to Nursing Care
• PML is thought to be caused by the JC virus. The JC virus was discovered 
after virions were observed on the bodies of oligodendrocytes. Although 
much has been learned about the virus, there is still a lot that needs to be 
discovered to gain a better understanding of the JC virus and PML (White & 
Khalili, 2011). 
• The JC virus is thought to affect 66-92% of the general population, as 
evidence by JC antibody prevalence in populations studied, and is acquired 
in childhood (White & Khalili, 2011). Despite the prevalence of JC 
antibodies, the actual occurrence of PML is low leading to the conclusion 
that the virus is re-activated, after a period of latency, in 
immunosuppressed individuals (White & Khalili, 2011).   
• The JC virus is transmitted during childhood and is thought to have initial 
portal of entries into the tonsils and GI tract. The body’s immune system 
fights the virus, defeats the virus, and then the virus enters a latent stage 
within the tonsils, bone and/or kidneys. The majority of people infected 
with the latent JC virus will never know the virus is there, unless they 
develop an autoimmune disorder or take immunosuppressive medications 
(White & Khalili, 2011). See Figure 2.
• The latent form of the JC virus can also be found in the bloodstream, 
particularly in B lymphocytes and can circulate in the brain (White & 
Khalili, 2011).
• Cytokines are released due to the autoimmune response in MS, causing a 
reactivation of the JC viral transcription and replication. A PML lesion on 
the brain can then develop due to the initial immunosuppression (White & 
Khalili, 2011).
• CD8 T cells play an important role in eliminating viruses and controlling 
their spread. Natalizumab suppresses T lymphocytes from crossing the 
blood-brain barrier, in an effort to control the demyelination in MS, which 
may prevent these cells from suppressing the latent JC virus adding to the 
reactivation and development of PML (White & Khalili, 2011). 
• The resulting development of PML plaques can lead to glial cell lysis and 
demyelination leading to neurological signs and symptoms (White & 
Khalili, 2011). 
Underlying Pathophysiology
• The pathophysiology is significant in that many patients diagnosed with MS and 
attempting or undergoing immunosuppression therapy may also have the 
antibodies for the JC virus which increases their risk of reactivating the infection, 
resulting in PML. Therefore, screening and close observation is warranted in the 
patient with MS.  
• The pathophysiology of the disease assists in diagnosing. The lesions that 
develop in the white matter of the brain can often be observed on MRI (see Figure 
3), the signs and symptoms come on gradually as the disease spreads throughout 
the brain, and cerebral spinal fluid can be analyzed for presence of the JC virus or 
antibodies (Berger et al., 2013). 
• Patients with MS that had prior immunosuppression therapy or another 
underlying immune disorder, develop PML at a rate of 13 to 1,000. The statistics 
are significant and warrant antibody testing and diligent surveillance for the JC 
virus and PML with attempted or long-term use of natalizumab (Susman, 2015).  
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